Your session is about to expire
← Back to Search
UCARTCS1A for Multiple Myeloma
Study Summary
This trial is testing a new cancer treatment to see if it is safe and effective for people with multiple myeloma who have relapsed or are refractory.
- Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- There may be additional requirements that you need to meet to be eligible for the study.You have not been treated before with experimental gene targeting CS1 or chimeric antigen receptor therapy targeting CS1.
- Group 1: Dose Escalation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment for this trial currently open?
"According to the information hosted on clinicaltrials.gov, this medical trial is still looking for participants. It was initially posted in November of 2019 and then last updated in August 2022."
To what extent is the population participating in this trial?
"Affirmative. According to clinicaltrials.gov information, this research project is presently seeking participants with the original listing being posted on November 21st 2019 and most recently modified by researchers on August 30th 2022. A total of 18 individuals from 7 distinct medical sites are required for this study."
Does this clinical trial accept participants aged 25 or older?
"This trial is enrolling patients aged 18 to 64. Subsequently, there are 40 trials for minors and 793 more for elderly participants."
How many research facilities are administering this trial?
"The trial is currently enrolling participants at 7 different study sites, located in San Antonio, Denver and Houston as well as several other spots. To minimise travel costs for yourself, select the closest available location to you."
Who is eligible to partipate in this trial?
"The prerequisites to enter this clinical trial are as follows: a diagnosis of relapsed or refractory multiple myeloma and an age between 18-64. At present, the team is recruiting 18 volunteers for the study."
Has the Food and Drug Administration sanctioned UCARTCS1A?
"With limited data supporting efficacy and safety, UCARTCS1A is given a score of 1 on the risk scale."
Share this study with friends
Copy Link
Messenger